Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN-T vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, causing bronchodilation, and also acts as an adenosine receptor antagonist.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
FDA-approved: Treatment of symptoms and prevention of asthma and reversible bronchospasm associated with chronic bronchitis and emphysema.,Off-label: Treatment of apnea of prematurity; as an adjunct in COPD exacerbations; prevention of neonatal apnea.
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
Oral: 200-400 mg twice daily (12-hourly). Dose titration: start 200 mg twice daily, increase by 200 mg/day every 3 days as tolerated to achieve serum theophylline level 5-15 mcg/m L. Maximum: 800 mg/day or 400 mg twice daily.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life is approximately 8 hours in healthy adults (range 3-13 hours). In neonates, it is prolonged (20-30 h). In smokers, half-life is reduced to 4-5 h. In patients with hepatic cirrhosis or heart failure, half-life may exceed 24 hours.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4; underwent N-demethylation and oxidation to active metabolites (caffeine and 3-methylxanthine).
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Approximately 90% is eliminated via hepatic metabolism (primarily via CYP1A2, CYP3A4), and about 10% is excreted unchanged in the urine. Renal clearance accounts for <10% of total clearance in adults. Biliary/fecal excretion is minimal (less than 5%).
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Approximately 40% bound to plasma proteins, primarily albumin. Binding is saturable and decreases in uremia.
65% bound to albumin
Approximately 0.45 L/kg (range 0.3-0.7 L/kg). This reflects distribution throughout total body water with some tissue binding.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral immediate-release: 96% (well absorbed). Oral sustained-release (SOMOPHYLLIN-T): approximately 90-100% relative to immediate-release. Intravenous: 100%.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No dose adjustment required in renal impairment. Theophylline pharmacokinetics minimally affected by GFR; however, monitor for accumulation in severe impairment (Cr Cl <10 m L/min) due to altered clearance.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh Class A: Reduce dose by 50% of normal dose. Child-Pugh Class B: Reduce dose by 70% of normal dose. Child-Pugh Class C: Reduce dose by 80% of normal dose; frequent monitoring of serum levels recommended.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Oral: 6-12 years: 10-16 mg/kg/day (max 400 mg/day) divided every 12 hours. 12-16 years: 10-16 mg/kg/day (max 600 mg/day) divided every 12 hours. Initiate at lower end of dose range and titrate based on therapeutic drug monitoring. Target trough serum concentration: 5-15 mcg/m L.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Elderly patients require cautious dosing: start at 200 mg once daily (or 100 mg twice daily) due to reduced clearance. Titrate slowly with frequent monitoring of serum levels. Target the lower end of therapeutic range (5-10 mcg/m L).
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
No FDA black box warning.
No FDA black box warning.
Risk of serious adverse events including seizures, cardiac arrhythmias, and death, especially with serum levels >20 mcg/m L.,Cautious use in patients with peptic ulcer disease, hyperthyroidism, seizure disorders, and cardiac disease.,Geriatric patients and those with hepatic impairment require dose adjustments.,Drug interactions with fluoroquinolones, macrolides, cimetidine, and allopurinol may increase theophylline levels.,Smoking induces metabolism, requiring higher doses.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to theophylline or any component of the formulation.,History of seizure disorder (relative, based on risk-benefit).,Cardiac arrhythmias (relative).
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid excessive consumption of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase theophylline side effects. Charcoal-broiled foods and high-protein diets may alter theophylline metabolism; maintain consistent intake. No significant interactions with other foods.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
First trimester: Limited data; no increased risk of major congenital anomalies reported in human studies. Second and third trimesters: Use with caution due to potential fetal tachycardia and jitteriness. High doses may lead to neonatal withdrawal. Overall, theophylline is considered relatively low risk compared to other xanthines.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Theophylline is excreted into breast milk with an M/P ratio of 0.6-0.7. Infant serum levels are typically subtherapeutic, but irritability and insomnia have been reported. Benefits of breastfeeding likely outweigh risks at maternal therapeutic doses.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Increased clearance (especially 2nd and 3rd trimesters) may require dose increases to maintain therapeutic levels. Postpartum: Clearance decreases rapidly within 6 weeks, requiring dose reduction to prevent toxicity. Therapeutic drug monitoring recommended.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
SOMOPHYLLIN-T is a sustained-release theophylline formulation. Monitor serum theophylline levels (target 10-20 mcg/m L) to avoid toxicity, especially in patients with hepatic impairment, heart failure, or those on drugs that inhibit CYP1A2 (e.g., cimetidine, fluoroquinolones). The extended-release formulation should not be crushed or chewed. Tachyphylaxis may occur with prolonged use.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take this medication exactly as prescribed, usually every 12 hours, with or without food.,Do not crush, chew, or break the tablet; swallow it whole.,Avoid large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase nervousness and palpitations.,Contact your doctor immediately if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not change your dose or stop taking without consulting your doctor, as it may cause worsening of asthma or COPD symptoms.,Inform all healthcare providers that you are taking theophylline, especially before surgery or any new medication.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMOPHYLLIN-T vs AEROLATE, answered by our medical review team.
SOMOPHYLLIN-T is a Bronchodilator that works by Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, causing bronchodilation, and also acts as an adenosine receptor antagonist.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMOPHYLLIN-T and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMOPHYLLIN-T is: Oral: 200-400 mg twice daily (12-hourly). Dose titration: start 200 mg twice daily, increase by 200 mg/day every 3 days as tolerated to achieve serum theophylline level 5-15 mcg/m L. Maximum: 800 mg/day or 400 mg twice daily.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMOPHYLLIN-T and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMOPHYLLIN-T is classified as Category C. First trimester: Limited data; no increased risk of major congenital anomalies reported in human studies. Second and third trimesters: Use with caution due to potential fetal tachy. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.